Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surovatamig in Primary Membranous Nephropathy
NCT07571746Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2026
- Primary completion
- Oct 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 9
01
Overview
A Phase 2 trial of surovatamig in primary membranous nephropathy (PMN), sponsored by AstraZeneca. Started Mar 2026; status: recruiting.
02
Drugs
surovatamig
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT07571746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07571746.